SAFE AND FUNCTIONAL HUMANIZED ANTIBODIES Russian patent published in 2017 - IPC G01N33/53 

FIELD: biochemistry.

SUBSTANCE: invention relates to biochemistry. Method of checking safety of examined antibody, binding to beta-amyloid, is disclosed. Glial macrophages are incubated with Aβ1-42 oligomers: i) in presence of examined antibody, ii) in presence of IgG1 antibody to beta-amyloid, including constant domain of human IgG1, and iii) without antibody. Then p38 MAP kinase activation is measured in glial macrophages. Examined antibody is identified as safe, if it induces intermediate level of p38 MAP kinase activation, i.e. activation level higher than that in presence of Aβ1-42 oligomers without antibody but lower than that in presence of Aβ1-42 oligomers and IgG1 antibody. Method of controlling safety of therapeutic course for amyloidosis treatment with analyzed antibody against beta-amyloid is also disclosed, which involves determination of level of p38 MAP kinase activation in glial macrophages, obtained from patient, and, if necessary, correction of therapeutic course so, that p38 MAP kinase activation remains on intermediate levels.

EFFECT: invention provides neuroprotection, mediated by antibody against beta-amyloid, without formation of pathogenetic inflammatory condition.

59 cl, 11 dwg, 2 tbl